We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Pfizer (PFE - Free Report) will announce quarterly earnings of $0.72 per share in its forthcoming report, representing a decline of 17.2% year over year. Revenues are projected to reach $16.13 billion, declining 3.1% from the same quarter last year.
The current level reflects a downward revision of 4.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Pfizer metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenues- Oncology- Elrexfio- Worldwide' will reach $87.50 million. The estimate indicates a change of +2.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Oncology- Tukysa- Worldwide' at $128.30 million. The estimate indicates a change of +16.6% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Oncology- Worldwide' will reach $4.13 billion. The estimate indicates a year-over-year change of -2.9%.
The consensus estimate for 'Revenues- Primary Care- Prevnar family- Worldwide' stands at $1.66 billion. The estimate indicates a year-over-year change of -5%.
Based on the collective assessment of analysts, 'Revenues- Oncology- Padcev- Total International' should arrive at $20.58 million. The estimate indicates a year-over-year change of +28.6%.
The combined assessment of analysts suggests that 'Revenues- Oncology- Talzenna- Total International' will likely reach $18.40 million. The estimate indicates a year-over-year change of +31.4%.
Analysts expect 'Revenues- Oncology- Adcetris- United States' to come in at $194.25 million. The estimate suggests a change of -7.5% year over year.
Analysts forecast 'Revenues- Oncology- Adcetris- Total International' to reach $5.50 million. The estimate indicates a year-over-year change of +10%.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tukysa- United States' of $87.40 million. The estimate indicates a year-over-year change of +10.6%.
According to the collective judgment of analysts, 'Revenues- Oncology- Tukysa- Total International' should come in at $40.90 million. The estimate points to a change of +27.8% from the year-ago quarter.
Analysts predict that the 'Revenues- Oncology- Elrexfio- United States' will reach $33.50 million. The estimate indicates a change of -9.5% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Oncology- Elrexfio- Total International' reaching $54.00 million. The estimate indicates a year-over-year change of +12.5%.
Over the past month, Pfizer shares have recorded returns of +3.3% versus the Zacks S&P 500 composite's +0.9% change. Based on its Zacks Rank #3 (Hold), PFE will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Pfizer (PFE - Free Report) will announce quarterly earnings of $0.72 per share in its forthcoming report, representing a decline of 17.2% year over year. Revenues are projected to reach $16.13 billion, declining 3.1% from the same quarter last year.
The current level reflects a downward revision of 4.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Pfizer metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenues- Oncology- Elrexfio- Worldwide' will reach $87.50 million. The estimate indicates a change of +2.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Oncology- Tukysa- Worldwide' at $128.30 million. The estimate indicates a change of +16.6% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Oncology- Worldwide' will reach $4.13 billion. The estimate indicates a year-over-year change of -2.9%.
The consensus estimate for 'Revenues- Primary Care- Prevnar family- Worldwide' stands at $1.66 billion. The estimate indicates a year-over-year change of -5%.
Based on the collective assessment of analysts, 'Revenues- Oncology- Padcev- Total International' should arrive at $20.58 million. The estimate indicates a year-over-year change of +28.6%.
The combined assessment of analysts suggests that 'Revenues- Oncology- Talzenna- Total International' will likely reach $18.40 million. The estimate indicates a year-over-year change of +31.4%.
Analysts expect 'Revenues- Oncology- Adcetris- United States' to come in at $194.25 million. The estimate suggests a change of -7.5% year over year.
Analysts forecast 'Revenues- Oncology- Adcetris- Total International' to reach $5.50 million. The estimate indicates a year-over-year change of +10%.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tukysa- United States' of $87.40 million. The estimate indicates a year-over-year change of +10.6%.
According to the collective judgment of analysts, 'Revenues- Oncology- Tukysa- Total International' should come in at $40.90 million. The estimate points to a change of +27.8% from the year-ago quarter.
Analysts predict that the 'Revenues- Oncology- Elrexfio- United States' will reach $33.50 million. The estimate indicates a change of -9.5% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Oncology- Elrexfio- Total International' reaching $54.00 million. The estimate indicates a year-over-year change of +12.5%.
View all Key Company Metrics for Pfizer here>>>Over the past month, Pfizer shares have recorded returns of +3.3% versus the Zacks S&P 500 composite's +0.9% change. Based on its Zacks Rank #3 (Hold), PFE will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .